Dual-action drugs targeting cannabinoid and PPAR receptors reduced binge eating in rats
In female rats with binge eating behavior, two dual-target drugs acting on CB1 cannabinoid and PPAR receptors successfully reduced compulsive palatable food consumption and restored disrupted hormonal and brain signaling.
Quick Facts
What This Study Found
OLHHA (CB1 antagonist/PPAR-alpha agonist) at 0.3 mg/kg and OLS (PPAR-alpha/TRPV1 agonist) at 6 mg/kg reduced aberrant palatable food consumption during binge eating tests. These treatments also partly restored disrupted leptin, opioid, and cannabinoid signaling in the hypothalamus and normalized POMC/AgRP/NPY pathways.
Key Numbers
OLHHA at 0.3 mg/kg and OLS at 6 mg/kg significantly reduced palatable food consumption during binge tests. Binge eating rats showed altered hypothalamus-pituitary axis activation with changes in leptin, opioid, and cannabinoid signaling and disrupted POMC/AgRP/NPY pathways.
How They Did This
Female rats underwent intermittent cycles of food restriction and frustration stress to induce binge eating behavior. Researchers measured plasma hormones, biochemical mediators, and gene/protein expression in the hypothalamus. Three dual-target drugs were tested: NF10-360 (dual PPAR-alpha/gamma agonist), OLS (PPAR-alpha/TRPV1 agonist), and OLHHA (CB1 antagonist/PPAR-alpha agonist).
Why This Research Matters
Binge eating disorder lacks effective pharmacological treatments. This study shows that drugs targeting both the endocannabinoid system and PPAR receptors can reduce binge eating behavior while correcting underlying neurochemical disruptions, suggesting a promising dual-target approach.
The Bigger Picture
Previous attempts to treat eating disorders by blocking CB1 receptors alone (rimonabant) failed due to psychiatric side effects. The dual-target approach, combining CB1 modulation with PPAR activation, may offer a way to get the appetite-suppressing benefits while avoiding the mood side effects that doomed single-target drugs.
What This Study Doesn't Tell Us
This is a rat model that uses stress-induced binge eating, which may not fully capture human binge eating disorder. Only female rats were studied. The treatments were given acutely, so long-term effects and safety are unknown.
Questions This Raises
- ?Would these dual-target drugs avoid the psychiatric side effects that plagued rimonabant?
- ?Do the same hypothalamic disruptions occur in humans with binge eating disorder?
- ?Could these drugs work for other eating disorders beyond binge eating?
Trust & Context
- Key Stat:
- Two dual-target drugs reduced binge eating while restoring disrupted hypothalamic signaling
- Evidence Grade:
- Animal study in female rats using an established binge eating model with biochemical and behavioral outcomes.
- Study Age:
- Published in 2025.
- Original Title:
- Targeting the endocannabinoid/paracannabinoid systems in binge eating behavior: Efficacy of dual ligands in a preclinical model.
- Published In:
- Pharmacological research, 222, 108005 (2025)
- Authors:
- de Ceglia, Marialuisa, Botticelli, Luca, Micioni Di Bonaventura, Emanuela, Vargas Fuentes, Antonio, Micioni Di Bonaventura, Maria Vittoria, Rodriguez de Fonseca, Fernando, Cifani, Carlo
- Database ID:
- RTHC-06315
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why target two receptor systems at once?
Blocking CB1 cannabinoid receptors alone (as rimonabant did) reduced appetite but caused serious psychiatric side effects. Combining CB1 modulation with PPAR receptor activation may provide appetite control while avoiding those problems.
What is binge eating disorder?
It is characterized by recurrent episodes of eating large amounts of palatable food in short periods, often triggered by stress, with feelings of loss of control. It affects approximately 2-3% of the population.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
Cite This Study
https://rethinkthc.com/research/RTHC-06315APA
de Ceglia, Marialuisa; Botticelli, Luca; Micioni Di Bonaventura, Emanuela; Vargas Fuentes, Antonio; Micioni Di Bonaventura, Maria Vittoria; Rodriguez de Fonseca, Fernando; Cifani, Carlo. (2025). Targeting the endocannabinoid/paracannabinoid systems in binge eating behavior: Efficacy of dual ligands in a preclinical model.. Pharmacological research, 222, 108005. https://doi.org/10.1016/j.phrs.2025.108005
MLA
de Ceglia, Marialuisa, et al. "Targeting the endocannabinoid/paracannabinoid systems in binge eating behavior: Efficacy of dual ligands in a preclinical model.." Pharmacological research, 2025. https://doi.org/10.1016/j.phrs.2025.108005
RethinkTHC
RethinkTHC Research Database. "Targeting the endocannabinoid/paracannabinoid systems in bin..." RTHC-06315. Retrieved from https://rethinkthc.com/research/de-2025-targeting-the-endocannabinoidparacannabinoid-systems
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.